A Phase 1 interventional study of BMS-708163 (Gamma-Secretase Inhibitor) and BMS-708163 (Gamma-Secretase Inhibitor) in Alzheimer's Disease, sponsored by Bristol-Myers Squibb. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-21.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing BMS 708163 in Alzheimer Disease — none open to participants now, none under way, none of them phase 3. BMS 708163 · Alzheimer Disease.
Among the 12 studies testing BMS 708163 in Alzheimer Disease, this one is the 3rd largest by enrollment, is the only one that started in 2007, is one of 10 in phase 1, and was the 12th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →None of the 12 studies testing BMS 708163 in Alzheimer Disease is open now. The open studies under Alzheimer Disease, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 31 across the 12 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
26 studies in Alzheimer Disease by Bristol-Myers Squibb: 12 open now, 13 under way, 10 of them phase 3. Of 13 finished, 0 (0%) have results posted.
Among the 26 studies in Alzheimer Disease by Bristol-Myers Squibb, this one is the 15th largest by enrollment, is the only one that started in 2007, is one of 12 in phase 1, and was the 12th registered.
Bristol-Myers Squibb’s Alzheimer Disease studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing BMS 708163 in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 26 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The primary objective is to assess the safety and tolerability of a single oral dose of BMS-708163 in healthy young male subjects and in elderly male and female subjects.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male subjects (age: 18 to 45 years)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy male subjects (age: 18 to 45 years)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy male subjects (age: 18 to 45 years)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy male subjects (age: 18 to 45 years)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy male subjects (age: 18 to 45 years). In Period 2: Subjects will receive BMS-708163 or placebo as a capsule formulation. In Period 3: Subjects will receive BMS-708163 or placebo as a capsule formulation within 5 minutes of consuming a standard high-fat breakfast on Day 1
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy male subjects (age: 18 to 45 years)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy male subjects (age: 18 to 45 years)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy male subjects (age: 18 to 45 years)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy, elderly male subjects (age: 60 years and greater)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy, elderly female subjects (age: 60 years and greater)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy male subjects (age: between 46 to 59 years)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy male and/or female subjects or subjects with MCI (age: between 60-74 years)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy male and/or female subjects or with AD or MCI (age: 75 years or greater)
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Healthy young male subjects
Drug: BMS-708163 (Gamma-Secretase Inhibitor) · Drug: Placebo matching BMS-708163
Oral Solution, Oral, 0.3 mg, Once daily, once
Oral Solution, Oral, 1.5 mg, Once daily, once
Oral Solution, Oral, 5.0 mg, Once daily, once
Oral Solution, Oral, 15.0 mg, Once daily, once
Oral Solution, Oral, 50 mg, Once daily, once
Oral Solution, Oral, 100 mg, Once daily, once
Oral Solution, Oral, 200 mg, Once daily, once
Oral Solution, Oral, 400 mg, Once daily, once
Capsule, Oral, 50 mg, Once daily, once
Oral Solution, Oral, 800 mg, Once daily, once
Oral Solution, Oral, 0 mg, Once daily, once
Capsule, Oral, 0 mg, Once daily, once
Safety and tolerability of Single doses of BMS-708163 in the range of 0.3 to 800 mg in the healthy subjects
Based on adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests
Time frame: Within 28 days of dosing
Effects of BMS-708163 on cortisol and QT interval corrected for heart rate
Time frame: Within 28 days of dosing
Effect of BMS-708163 on thyroid stimulating hormone (TSH), free triiodothyronine (T3), free thyroxine (T4), and lymphocyte subsets
Time frame: Within 28 days of dosing
Bioavailability of BMS-708163 from a capsule formulation relative to a solution formulation
Time frame: Within 28 days of dosing
Effect of food on the PK of BMS-708163 administered as a capsule formulation
Time frame: Within 28 days of dosing
Maximum observed plasma concentration (Cmax) of BMS-708163
Time frame: Within 28 days of dosing
Time of maximum observed plasma concentration (Tmax) of BMS-708163
Time frame: Within 28 days of dosing
Area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-708163
Time frame: Within 28 days of dosing
Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-708163
Time frame: Within 28 days of dosing
Plasma half-life (T-HALF) of BMS-708163
Time frame: Within 28 days of dosing
No study locations are listed for this record.
The record gives a start of Jun 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BMS 708163